Amarin (NASDAQ:AMRN) was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a report issued on Thursday.
A number of other equities research analysts also recently weighed in on the stock. Cantor Fitzgerald set a $10.00 price target on shares of Amarin and gave the company a “buy” rating in a report on Wednesday, December 13th. ValuEngine downgraded shares of Amarin from a “hold” rating to a “sell” rating in a report on Thursday, November 16th. Finally, Zacks Investment Research downgraded shares of Amarin from a “hold” rating to a “sell” rating in a report on Tuesday, December 12th. Two analysts have rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $7.75.
Shares of Amarin (NASDAQ:AMRN) opened at $3.61 on Thursday. Amarin has a 1-year low of $2.85 and a 1-year high of $4.60. The company has a debt-to-equity ratio of -1.12, a current ratio of 1.41 and a quick ratio of 1.13. The firm has a market cap of $1,050.00, a PE ratio of -14.44 and a beta of 0.57.
Amarin (NASDAQ:AMRN) last issued its quarterly earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.05) by ($0.03). The business had revenue of $53.87 million for the quarter, compared to the consensus estimate of $52.73 million. During the same period last year, the firm earned ($0.10) earnings per share. The company’s revenue was up 39.2% compared to the same quarter last year. equities research analysts anticipate that Amarin will post -0.33 earnings per share for the current fiscal year.
In other Amarin news, General Counsel Joseph T. Kennedy sold 51,106 shares of the business’s stock in a transaction dated Wednesday, January 17th. The stock was sold at an average price of $4.10, for a total transaction of $209,534.60. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Steven B. Ketchum sold 64,683 shares of the business’s stock in a transaction dated Friday, January 5th. The stock was sold at an average price of $4.40, for a total value of $284,605.20. The disclosure for this sale can be found here. Insiders sold a total of 426,720 shares of company stock valued at $1,814,296 over the last three months. 3.72% of the stock is owned by corporate insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. OppenheimerFunds Inc. raised its holdings in Amarin by 20.9% during the 4th quarter. OppenheimerFunds Inc. now owns 7,897,310 shares of the biopharmaceutical company’s stock worth $31,668,000 after buying an additional 1,365,720 shares during the period. Clearbridge LLC raised its holdings in Amarin by 9.8% during the 4th quarter. Clearbridge LLC now owns 4,867,366 shares of the biopharmaceutical company’s stock worth $19,518,000 after buying an additional 435,340 shares during the period. Alkeon Capital Management LLC acquired a new stake in Amarin during the 3rd quarter worth about $7,875,000. Two Sigma Investments LP raised its holdings in Amarin by 41.1% during the 4th quarter. Two Sigma Investments LP now owns 1,547,977 shares of the biopharmaceutical company’s stock worth $6,207,000 after buying an additional 450,755 shares during the period. Finally, Highland Capital Management LP raised its holdings in Amarin by 152.5% during the 4th quarter. Highland Capital Management LP now owns 1,197,000 shares of the biopharmaceutical company’s stock worth $4,800,000 after buying an additional 723,000 shares during the period. Hedge funds and other institutional investors own 38.20% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Amarin (AMRN) Stock Rating Upgraded by BidaskClub” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this report on another domain, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The correct version of this report can be read at https://www.dispatchtribunal.com/2018/03/15/amarin-amrn-stock-rating-upgraded-by-bidaskclub.html.
Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.
Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.